Latest News

FDA accepts Tuzistra™ XR (CCP-01) NDA for full review

Vernalis plc and Tris Pharma, Inc. ("Tris") are pleased to announce that the U.S. Food and Drug Administration ("FDA") has confirmed that the New Drug Application ("NDA") for TuzistraTM XR ("CCP-01") has been accepted for full review.


Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form